Viewing Study NCT00086541



Ignite Creation Date: 2024-05-05 @ 11:35 AM
Last Modification Date: 2024-10-26 @ 9:10 AM
Study NCT ID: NCT00086541
Status: COMPLETED
Last Update Posted: 2019-11-25
First Post: 2004-07-02

Brief Title: Daily-Dose Consensus Interferon and Ribavirin Efficacy of Combined Therapy
Sponsor: Bausch Health Americas Inc
Organization: Bausch Health Americas Inc

Study Overview

Official Title: A Phase 3 Randomized Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 Infergen CIFN Plus Ribavirin Administered Daily for 48 Weeks Versus No Treatment in Hepatitis C Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa Plus Ribavirin Therapy
Status: COMPLETED
Status Verified Date: 2019-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This Phase 3 clinical study is designed to evaluate the safety tolerability and efficacy of two dose levels of Infergen interferon alfacon-1 CIFN plus Ribavirin administered daily for 48 weeks and no treatment in patients chronically infected with hepatitis C who are nonresponders to previous pegylated interferon alfa plus ribavirin therapy

Patients are randomized 111 to receive Interferon Alfacon-1 9 or 15 µg Ribavirin both administered daily or no treatment for up to 48 weeks

The protocol and informed consent form that will be used must be approved by the Investigators Institutional Review Board IRBIndependent Ethics Committee IEC before the study is initiated
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
DIRECT 1 None None None